Darah focuses her practice on the representation of both underwriters and issuers on a variety of capital markets transactions. Darah also regularly counsels publicly traded companies on general corporate matters, including SEC reporting and corporate governance.
Immunology Company argenx Announces $1.27 Billion Global Offering
July 26, 2023
Cooley advised J.P. Morgan, Morgan Stanley, Goldman Sachs, BofA Securities and TD Cowen, representatives of the several underwriters, in the $1.27 billion follow-on offering by argenx SE, a global immunology company.
Prelude Therapeutics – $100 Million Follow-on Offering
May 18, 2023
Cooley advised the underwriters in Prelude Therapeutics’ $100 million follow-on offering. Prelude Therapeutics is a clinical-stage precision oncology company developing innovative drug candidates targeting critical cancer cell pathways. Lawyers Richard Segal, Div Gupta, Darah Protas, Sam Paullin and Katie Lapidus led the Cooley team.
Karuna Therapeutics – $460 Million Follow-on Offering
March 21, 2023
Cooley advised the underwriters in Karuna Therapeutics’ $460 million follow-on offering. Karuna is a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions. Goldman Sachs & Co., JP Morgan, Morgan Stanley, Stifel, and Guggenheim Securities acted as joint book-running managers for the offering. Partners Richard Segal, Div Gupta and Jean Park led the Cooley team.
Apellis Pharmaceuticals – $402.5 Million Follow-on Offering
February 22, 2023
Cooley advised the underwriters in Apellis Pharmaceuticals’ $402.5 million follow-on offering. Apellis is a global biopharmaceutical company committed to leveraging courageous science, creativity and compassion to deliver life-changing therapies. JP Morgan, Goldman Sachs & Co., and Evercore ISI acted as joint book-running managers for the offering, while Baird and Raymond James acted as co-managers. Partners Div Gupta and Richard Segal led the Cooley team.
